Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.
Pratley RE, Jacob S, Baek S, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Shaunik A, Yoon KH. Pratley RE, et al. Among authors: baek s. BMJ Open Diabetes Res Care. 2022 Jan;10(1):e002207. doi: 10.1136/bmjdrc-2021-002207. BMJ Open Diabetes Res Care. 2022. PMID: 35042751 Free PMC article. Clinical Trial.
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K; AMPLITUDE-O Trial Investigators. Gerstein HC, et al. N Engl J Med. 2021 Sep 2;385(10):896-907. doi: 10.1056/NEJMoa2108269. Epub 2021 Jun 28. N Engl J Med. 2021. PMID: 34215025 Free article. Clinical Trial.
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, Del Prato S, Lopes RD, Niemoeller E, Khurmi NS, Baek S, Gerstein HC. Lam CSP, et al. Among authors: baek s. Circulation. 2022 Feb 22;145(8):565-574. doi: 10.1161/CIRCULATIONAHA.121.057934. Epub 2021 Nov 14. Circulation. 2022. PMID: 34775781 Free article. Clinical Trial.
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
Gerstein HC, Li Z, Ramasundarahettige C, Baek S, Branch KRH, Del Prato S, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N. Gerstein HC, et al. Among authors: baek s. Circulation. 2023 Mar 28;147(13):1004-1013. doi: 10.1161/CIRCULATIONAHA.122.063716. Epub 2023 Feb 20. Circulation. 2023. PMID: 36802715 Free article. Clinical Trial.
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
Aroda VR, Frias JP, Ji L, Niemoeller E, Nguyên-Pascal ML, Denkel K, Espinasse M, Guo H, Baek S, Choi J, Lingvay I. Aroda VR, et al. Among authors: baek s. Diabetes Obes Metab. 2023 Aug;25(8):2084-2095. doi: 10.1111/dom.15079. Epub 2023 Apr 26. Diabetes Obes Metab. 2023. PMID: 37013892
A double-blind, placebo-controlled, single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long-acting glucagon analogue, in healthy subjects.
Huh KY, Hwang JG, Shin W, Baek S, Choi J, Lee N, Cho YM, Lee H. Huh KY, et al. Among authors: baek s. Diabetes Obes Metab. 2022 Mar;24(3):411-420. doi: 10.1111/dom.14590. Epub 2021 Nov 24. Diabetes Obes Metab. 2022. PMID: 34726329 Clinical Trial.
A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study.
Abdelmalek MF, Suzuki A, Sanchez W, Lawitz E, Filozof C, Cho H, Baek E, Choi J, Baek S. Abdelmalek MF, et al. Among authors: baek s, baek e. Contemp Clin Trials. 2023 Jul;130:107176. doi: 10.1016/j.cct.2023.107176. Epub 2023 Apr 5. Contemp Clin Trials. 2023. PMID: 37028504 Clinical Trial.
A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects.
Jeon Y, Lee N, Baek S, Choi J, Jhee S, Lee H. Jeon Y, et al. Among authors: baek s. Drugs R D. 2022 Mar;22(1):71-87. doi: 10.1007/s40268-021-00379-8. Epub 2022 Jan 6. Drugs R D. 2022. PMID: 34993933 Free PMC article. Clinical Trial.
4,495 results